Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
Nutrients · 31.01.2023 · 15 (3) · 718
DOI: 10.3390/nu15030718 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 31.01.2023. Verfasst von Martin Magner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, General University Hospital, 128 08 Pragu…. Hauptthemen laut MEDLINE: Autistic Disorder, Autism Spectrum Disorder. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of the Agriculture of the Czech Republic, Ministry of the Health of the Czech Republic.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic behaviour. We performed a prospective double-blind placebo-controlled study to examine the possible effect of SFN in a paediatric cohort aged three to seven years based on measurements of the Autism Diagnostic Observation Schedule-2 (ADOS-2), the Social Responsiveness Scale-2 (SRS-2), and the Aberrant Behaviour Checklist (ABC). The study consisted of three visits over the duration of 36 weeks (baseline, 18 weeks, and 36 weeks). Twenty-eight of the 40 randomized children completed the study. The mean total raw scores on ABC and SRS-2 improved in both groups, but none of the changes reached statistical significance (ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576; SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435). Changes in the assessment of the ADOS-2 subscale scores also did not differ between the two study cohorts (ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414). We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3–7 years that were treated with sulforaphane.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, General University Hospital, 128 08 Prague 2, Czech Republic.
- National Institute for Autism, 180 00 Prague 8, Czech Republic.
- Food Research Institute Prague, 102 00 Prague 10, Czech Republic.
- Global Change Research Institute CAS, 603 00 Brno, Czech Republic.
- Faculty of Horticulture, Mendel University in Brno, 691 44 Lednice, Czech Republic.
- Pure Food Norway, 1400 Ski, Norway.
ORCID-Profile: Martin Magner, Milan Houška, Jan Tříska
Förderung
- Ministry of the Agriculture of the Czech Republic
- Ministry of the Health of the Czech Republic
Zitieren
APA
Magner, M., Thorová, K., Župová, V., Houška, M., Švandová, I., Novotná, P., Tříska, J., Vrchotová, N., Soural, I., & Jílek, L. (2023). Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study. Nutrients, 15(3), 718. https://doi.org/10.3390/nu15030718
Vancouver
Magner M, Thorová K, Župová V, Houška M, Švandová I, Novotná P, et al. Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study. Nutrients. 2023;15(3):718. doi:10.3390/nu15030718
BibTeX
@article{Magner2023,
author = {Magner, Martin and Thorová, Kateřina and Župová, Veronika and Houška, Milan and Švandová, Ivana and Novotná, Pavla and Tříska, Jan and Vrchotová, Naděžda and Soural, Ivo and Jílek, Ladislav},
title = {Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {3},
pages = {718},
doi = {10.3390/nu15030718}
}
EUVIMED